Committee hears bill to let DHHS‑registered harm‑reduction groups use drug‑checking equipment

Representative Jody Newell told the Senate Judiciary Committee that HB226 would allow organizations registered with the New Hampshire Department of Health and Human Services to use drug‑checking equipment to learn what is on local drug supplies. "We are still losing loved ones to overdose," she said, urging the committee to consider tools that go beyond fentanyl test strips.

The bill would add definitions and carve out an exemption so that drug‑checking equipment and related materials used by agents of organizations explicitly authorized by a state, county, municipality or public health department would not be treated as drug paraphernalia. Newell said the change would make clear that such testing is permitted, that it could be eligible for opioid abatement and federal funds, and that the statute would not require use of general fund dollars. She also emphasized the bill maintains the earlier decriminalization language for fentanyl and xylazine test strips while expanding exemptions for more sophisticated testing.

Lauren McGinley, executive director of the New Hampshire Harm Reduction Coalition, told the committee the difference between test strips and comprehensive checking is material to public health: "What's in it is what's really critical to know right now to public health professionals," she said. McGinley described how the coalition and local programs have used test strips and said the ability to identify multiple compounds and approximate potency could change counseling, wound care and outreach. She told the committee her network distributed "about 30,000 test strips" in the past year.

Medical witnesses described clinical reasons drug checking matters. Dr. Carrie Nolte, a family nurse practitioner and researcher working with harm‑reduction sites, said identifying substances such as xylazine helped clinicians recognize emerging wounds and change treatment and referral patterns.

Opponents including Major Bill Bright of the New Hampshire State Police and representatives of municipal police departments raised legal and operational concerns. Bright said the bill's language around a "nominal amount" of controlled substances is undefined and could create ambiguity for investigators and prosecutors. He also warned the measure could interfere with supply‑side investigations: "I think there's some things in this bill that complicate... what law enforcement is trying to do in cutting off the the supply chain," he said. Elizabeth Sargent, speaking for the New Hampshire Association of Chiefs of Police, echoed concerns that broad exemptions could make investigations harder if people claim they are "agents" or part of harm‑reduction organizations.

Committee members pressed authors and witnesses on who could possess equipment, whether outreach testing in the community would be covered, and whether the bill would provide immunity for people transporting substances to testing locations. Newell and coalition witnesses said the draft limits use to agents of organizations registered with DHHS and that the measure removed earlier proposals to allow broader public drop‑off testing.

No committee vote on HB226 is recorded in the public transcript; members asked follow‑up questions and discussed drafting concerns and the definition of "nominal amount."